Research · Sep 3, 2026
[IONS] Ionis Pharmaceuticals Thesis 2026: Wainua Tryngolza Launch Drives Independent Commercial Recovery
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) FY2025 revenue ~$590-680M (-15 to -1%) with adj. EPS ~-$2.20 to -$1.65 reflecting selected post-December 2024 ~$30-50M aggregate Tryngolza (olezarsen) FDA approval (selected first-in-class novel familial chylomicronemia syndrome (FCS) treatment) + selected continued post-2024 ~$200-260M aggregate Spinraza royalty revenue (~30-40% aggregate revenue mix; selected continued Biogen Spinraza partnership) + selected post-December 2023 ~$50-100M aggregate Wainua (eplontersen) Ionis-AstraZeneca hereditary transthyretin (hATTR) amyloidosis launch + selected continued post-2024 selected various pipeline + selected continued post-2024 selected primary independent commercial transformation toward selected various Ionis-owned pipeline under continued President + CEO Brett Monia since 2020 (~5-year tenure as Ionis Pharmaceuticals CEO). One of the world's leading RNA-targeted therapeutics + antisense oligonucleotide (ASO) drug development companies. Founded 1989 as Isis Pharmaceuticals in Carlsbad California by Stanley Crooke (~36-year heritage); selected post-1991 NASDAQ listing IPO; selected post-2015 Isis → Ionis name change; selected post-2016 Spinraza FDA approval; selected post-2020 Brett Monia CEO appointment; selected post-December 2023 Wainua FDA approval; selected post-December 2024 Tryngolza FDA approval. Headquartered in Carlsbad California; ~900+ employees globally with ~$590-680M revenue. Three primary product + pipeline segments: Ionis-owned Commercial (~25-30% ~$150-200M), Spinraza Royalty + Various Royalties (~35-40% ~$220-300M), R&D Revenue + Pipeline (~30-35% ~$200-250M). Geographic mix: US ~60-65% + Europe + selected various ~25-30% + selected various ~10%. Wainua + Tryngolza independent commercial launch: post-December 2023 Wainua + post-December 2024 Tryngolza FDA approvals. Spinraza royalty + Ionis-owned pipeline: selected continued Biogen Spinraza partnership + donidalorsen + olezarsen + pelacarsen + selected various RNA-targeted pipeline. President + CEO Brett Monia since 2020 (~5-year tenure); CFO Beth Hougen. Capital + cash position: ~$1.6-1.9B aggregate cash + investments balance; ~$0M aggregate net debt position; modest opportunistic buybacks; selected pathway to GAAP profitability inflection FY2026-2028 driven by Wainua + Tryngolza commercialization. FY2026 thesis: Wainua + Tryngolza independent commercial launch + Spinraza royalty + selected various Ionis-owned pipeline + ~$1.6-1.9B aggregate cash + investments balance + ~$0M aggregate net debt + selected pathway to GAAP profitability inflection FY2026-2028 + selected potential post-2024 capital return optionality. Risks: Alnylam + RNA-targeted competition, Spinraza generic erosion + Biogen + Roche Risdiplam SMA, Wainua + Tryngolza commercialization, clinical pipeline risk, GAAP profitability inflection trajectory.